Genetic study based on the sequencing of the tumor sample that provides information on the therapeutic options based on the mutational profile.
This massive sequencing platform allows the simultaneous identification of different molecular alterations in clinically relevant genes. The integration of the sequencing data with the OncoNIM Biomarker database makes it possible to issue a report that includes:
- Recommendations from the treatment guidelines of the ESMO and NCCN
- The approval status of drugs in the EMEA and/or FDA
- The availability of clinical trials in progress
Colon and Lung
Gene panel optimized for the detection of point mutations in tumor samples of colorectal or pulmonary origin. The mutational profile is integrated into the OncoNIM® Biomarker database to provide the specialist with relevant information on possible therapeutic options.
The test identifies recurrent mutations in 22 genes selected because they are prognostic and/or predictive markers, or potential therapeutic targets, currently validated or under evaluation in ongoing clinical trials.
Delivery of results: 21 working days after receipt of sample.
NGS panel developed for the detection of fusion genes in lung cancer. Analyzes four genes involved in a total of 24 fusion genes or rearrangements.
The mutational profile is integrated into the OncoNIM® Biomarker database for its correlation with available treatments and clinical trials.
Delivery of results: 21 working days from receipt of the sample.
NGS platform for the detection of point mutations in hotspot regions, fusion transcripts and CNVs, through the study of DNA and RNA from solid tumor samples. The mutational profile is integrated into the OncoNIM® Biomarker database to provide the specialist with relevant information on possible therapeutic options.
The test includes 52 genes, widely characterized in the literature and in clinical guidelines, and for which actionable mutations have been described and that approved drugs exist or are in clinical trials.